Moleculin Biotech (MBRX) Change in Accured Expenses (2016 - 2025)

Moleculin Biotech's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $218000.0 for Q4 2025.

• In Q4 2025, Change in Accured Expenses fell 22.42% year-over-year to $218000.0; the TTM figure through Dec 2025 stood at $17000.0 (up 101.53% YoY), while the FY2025 annual figure was $17000.0, up 101.53% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $218000.0, up from -$549000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.4 million in Q4 2023, with the low at -$1.1 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $75000.0 (2022), against an average of $56100.0.
• Peak annual rise in Change in Accured Expenses reached 3330.67% in 2023, while the deepest fall reached 1611.36% in 2023.
• Moleculin Biotech's Change in Accured Expenses stood at $11000.0 in 2021, then sank by 781.82% to -$75000.0 in 2022, then jumped by 3330.67% to $2.4 million in 2023, then plunged by 88.4% to $281000.0 in 2024, then slipped by 22.42% to $218000.0 in 2025.
• Business Quant data shows MBRX's Change in Accured Expenses at $218000.0 in Q4 2025, -$549000.0 in Q3 2025, and -$390000.0 in Q2 2025.